CLINICAL TRIALS PROFILE FOR FLUZOPARIB
✉ Email this page to a colleague
Clinical Trials for Fluzoparib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02575651 ↗ | A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | Completed | 307 Hospital of PLA | Phase 1 | Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated. |
| NCT02575651 ↗ | A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | Completed | Beijing Cancer Hospital | Phase 1 | Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated. |
| NCT02575651 ↗ | A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | Completed | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated. |
| NCT02759666 ↗ | A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors | Completed | Atridia Pty Ltd. | Phase 1 | This is an open-label, multicenter, non-randomized, dose-escalation phase 1 trial to evaluate the safety and tolerability of SHR3162 in participants with advanced solid tumors. |
| NCT03075462 ↗ | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | Unknown status | Beijing Cancer Hospital | Phase 1 | Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Fluzoparib
Condition Name
Clinical Trial Locations for Fluzoparib
Clinical Trial Progress for Fluzoparib
Clinical Trial Phase
Clinical Trial Sponsors for Fluzoparib
Sponsor Name
